Edition:
India

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.60USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$4.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,274
52-wk High
$18.30
52-wk Low
$4.30

Chart for

About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic... (more)

Overall

Beta: --
Market Cap(Mil.): $611.97
Shares Outstanding(Mil.): 35.48
Dividend: --
Yield (%): --

Financials

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

09 Mar 2018

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

06 Feb 2018

Competitors

Earnings vs. Estimates